Glycogen Storage Disease Type IIb
Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold
Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event